Bor Gizem, Mat Azmi Intan Diana, Yaghmur Anan
Department of Pharmacy, Faculty of Health & Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark.
Centre of Foundation Studies for Agricultural Science & Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor Darul Ehsan, Malaysia.
Ther Deliv. 2019 Feb;10(2):113-132. doi: 10.4155/tde-2018-0062. Epub 2019 Jan 25.
The emergence of nanomedicine as an innovative and promising alternative technology shows many advantages over conventional cancer therapies and provides new opportunities for early detection, improved treatment, and diagnosis of cancer. Despite the cancer nanomedicines' capability of delivering chemotherapeutic agents while providing lower systemic toxicity, it is paramount to consider the cancer complexity and dynamics for bridging the translational bench-to-bedside gap. It is important to conduct appropriate investigations for exploiting the tumor microenvironment, and achieving a more comprehensive understanding of the fundamental biological processes in cancer and their roles in modulating nanoparticle-protein interactions, blood circulation, and tumor penetration. This review provides an overview of the current cancer nanomedicines, the major challenges, and the future opportunities in this research area.
纳米医学作为一种创新且有前景的替代技术的出现，相较于传统癌症疗法显示出诸多优势，并为癌症的早期检测、改善治疗和诊断提供了新机遇。尽管癌症纳米药物有能力递送化疗药物并降低全身毒性，但考虑癌症的复杂性和动态性对于弥合从实验台到病床的转化差距至关重要。开展适当的研究以利用肿瘤微环境，并更全面地了解癌症中的基本生物学过程及其在调节纳米颗粒 - 蛋白质相互作用、血液循环和肿瘤渗透中的作用，这一点很重要。本综述概述了当前的癌症纳米药物、该研究领域的主要挑战和未来机遇。
